Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 3, pp. 238-251
Open Access | Times Cited: 1693

Showing 1-25 of 1693 citing articles:

Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato, et al.
Science (2021) Vol. 371, Iss. 6529
Open Access | Times Cited: 2727
Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1749
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang, Fabian Schmidt, Yiska Weisblum, et al.
Nature (2021) Vol. 592, Iss. 7855, pp. 616-622
Open Access | Times Cited: 1438
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Petra Mlčochová, Steven A. Kemp, Mahesh Shanker Dhar, et al.
Nature (2021) Vol. 599, Iss. 7883, pp. 114-119
Open Access | Times Cited: 1279
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 622-625
Open Access | Times Cited: 1233
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1106
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 467-484.e15
Open Access | Times Cited: 921
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
Cell (2021) Vol. 185, Iss. 3, pp. 447-456.e11
Open Access | Times Cited: 869
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 3, pp. 477-488.e4
Open Access | Times Cited: 809
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
SARS-CoV-2 pathogenesis
Mart M. Lamers, Bart L. Haagmans
Nature Reviews Microbiology (2022) Vol. 20, Iss. 5, pp. 270-284
Open Access | Times Cited: 685
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Aekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2422-2433.e13
Open Access | Times Cited: 668
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Robert Gottlieb, Carlos Vaca, Roger Paredes, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 4, pp. 305-315
Open Access | Times Cited: 633
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 21, pp. 1941-1950
Open Access | Times Cited: 630
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Science Immunology (2021) Vol. 6, Iss. 62
Open Access | Times Cited: 496
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Tyler N. Starr, Allison J. Greaney, Adam S. Dingens, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 4, pp. 100255-100255
Open Access | Times Cited: 493
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
Caroline Junqueira, Ângela C. Crespo, Shahin Ranjbar, et al.
Nature (2022) Vol. 606, Iss. 7914, pp. 576-584
Open Access | Times Cited: 440
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Ronza Najjar‐Debbiny, Naomi Gronich, Regina Weber, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e342-e349
Open Access | Times Cited: 432
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
Meagan P. O’Brien, Eduardo Forleo‐Neto, Bret J. Musser, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 13, pp. 1184-1195
Open Access | Times Cited: 419
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 23
Open Access | Times Cited: 391
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19
Rohitash Yadav, Jitendra Kumar Chaudhary, Neeraj Jain, et al.
Cells (2021) Vol. 10, Iss. 4, pp. 821-821
Open Access | Times Cited: 382
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Sanjay Ramakrishnan, Dan V. Nicolau, Beverly Langford, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 7, pp. 763-772
Open Access | Times Cited: 381
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen, Haili Tang, Charlene McDanal, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 529-539.e3
Open Access | Times Cited: 377
Page 1 - Next Page

Scroll to top